Raadpleeg ook literatuurlijst niet-toxische middelen en behandelingen specifiek bij baarmoederhalskanker en baarmoederkanker van arts-bioloog drs. Engelbert Valstar.

28 november 2019: Bron: Asian Pacific Journal of Cancer prevention

Wanneer patienten met gevorderde baarmoederhalskanker naast hun standaard chemokuren van cisplatin en/of taxol daarbij vitamine A (tablet met 8.0000 IU 3x daags) krijgen toegediend dan blijkt de responskans en effectiviteit van de chemo toe te nemen.

Van patienten uit de combinatiegroep van neo adjuvante chemo (NAC) plus vitamine A bereikte 73 procent een CR = complete remissie of PR = gedeeltelijke remissie en 26,7 procent geen respons tegenover de patienten die alleen met NAC zonder vitamine A werd behandeld, bleek dat 6,7% van de patiënten een CR = volledige respons, 33,3% een PR = gedeeltelijke respons en 60% geen respons kreeg

Dit blijkt uit een kleinschalige maar wel dubbel blind gerandomiseerde studie bij 30 patienten met gevorderde baarmoederhalskanker.

Uit het studierapport:

Vergelijking van klinische respons na interventie

Uit de gegevens van de totale studie werd een klinische respons gezien van 56,7% (n = 17). Maar 43,3% (n = 13) vertoonde geen klinische respons, met name de Neo Adjuvante Chemo groep (NAC) (60%). De groep die werd behandeld met NAC + Vitamine A toonde aan dat wel een meerderheid van de patiënten (73,3%) een klinische respons had bereikt.
De officieel geregistreerde vastgelegde resultaten waren een CR = volledige respons op de behandeling bij 13,3% van de patiënten, gevolgd door een PR = gedeeltelijke respons bij 43,3% van de patiënten. De resterende 43,3% vertoonde geen respons op de behandeling.

Observatie van de groep die alleen met NAC werd behandeld, bleek dat 6,7% van de patiënten een CR = volledige respons, 33,3% een PR = gedeeltelijke respons en 60% geen respons kreeg.

De groep die NAC + Vitamine A kreeg, kreeg daarentegen een veel hogere respons met 20% die een CR = volledige respons vertoonde, een PR = gedeeltelijke respons van 53,3% en geen respons van 26,7%.

Het is duidelijk dat de groep die NAC + Vitamine A kreeg een groter deel van de volledige respons op de behandeling teweegbracht dan degenen die NAC alleen kregen.

Dit betekent volgens de onderzoekers dat de toediening van vitamine A de klinische respons in grotere mate heeft beïnvloed bij patiënten met gevorderde baarmoederhalskanker.

Het volledige studierapport:

Outcome of Combined Neoadjuvant Chemotherapy and Vitamin A in Advanced Cervical Carcinoma: A Randomized Double-Blind Clinical Trial

is gratis in te zien.

Hier het abstract van de studie plus referentielijst.

Asian Pac J Cancer Prev. 2019; 20(7): 2213–2218.

doi: 10.31557/APJCP.2019.20.7.2213

PMCID: PMC6745224

PMID: 31350987

Outcome of Combined Neoadjuvant Chemotherapy and Vitamin A in Advanced Cervical Carcinoma: A Randomized Double-Blind Clinical Trial

Rizal Sanif Sanusi*

Author information Article notes Copyright and License information Disclaimer

Go to:

Abstract

Background:

The latest World Health Organization (WHO) inquiry on the epidemiology of cervical cancers indicate there are approximately 528,000 new cases per year, ranking fourth after breast, colorectal and lung cancer. The validity of neoadjuvant chemotherapy (NAC) alone in advanced cervical cancer is still being debated. NAC induces tumor shrinkage prior to pursuing surgery. NAC also has the benefit of sterilizing the lymph nodes and parametria, thereby lowering the need for adjuvant therapy after surgery. This research aims to determine the impact on the treatment of advanced cervical carcinoma with NAC, with the additional provision of Vitamin A during treatment to assess the factors that could affect the outcome of clinical treatment.

Methodology:

The research methodology and design of this study is a randomized double-blind clinical trial to compare the effects of treatment with NAC and treatment with NAC + Vitamin A, in advanced cervical carcinoma. Both study groups received treatments consisting of a regime of cisplatin and paclitaxel. The study was conducted at the General Hospital of Dr. Mohammad Hoesin. The total number of patients recruited for the trial was 30 with 15 patients per treatment arm. One group received NAC consisting of cisplatin and paclitaxel and the remaining 15 patients received NAC + Vitamin A.

Results:

The addition of Vitamin A was found to be much better in influencing the clinical response in the treatment of advanced cervical carcinoma, although this was not statistically significant. However, a larger sample size with the reported proportion of higher positive outcome for NAC + Vitamin A may be statistically significant.

Conclusion:

Based on the results, Vitamin A supplementation in the treatment of advanced cervical carcinoma with neoadjuvant chemotherapy may play a crucial role in the treatment of cervical carcinoma.

In conclusion, although tumour shrinkage in patients administered NAC + Vitamin A does not appear to be significantly different (p=0.139) to the shrinkage observed with NAC alone, it is apparent that the shrinkage was more pronounced (75%) when Vitamin A was administered together with NAC as opposed to the lower shrinkage (40%) observed with NAC alone. This is indication that Vitamin A may have enhanced the treatment outcome observed in the present study. It appears highly plausible that if the sample size was larger, the difference between percentage tumour shrinkage for the treatments groups of NAC and NAC + Vitamin A may be more statistically significant.

The results of this study indicate that the addition of Vitamin A caused a statistically significant reduction in tumour size of cervical carcinomas. In the event a statistically insignificant positive response is observed after three cycles of chemotherapy, it appears justified to continue with chemotherapy. In the light of past and present findings, it is reasonable to speculate that the significant reduction in tumour volume may well be attributed to the combined effects of NAC and Vitamin A. It therefore appears reasonable to suggest that Vitamin A supplementation should be provided on a routine basis in the treatment of advanced cervical carcinoma with neoadjuvant chemotherapy (NAC).

Go to:

References

Budhu AS, Noy N. Direct channelling of Retinoic Acid be- tween cellular retinoic Acid-Binding protein II and Retinoic Acid receptor Sensitizes mammary carcinoma cells to Retinoic Acid-Induced growth arrest. Mol Cell Biol. 2002;22:2632–41. [PMC free article] [PubMed] [Google Scholar]
European Food Safety Authority. Scientific opinion on dietary reference values for vitamin A EFSA Panel on Dietetic Products, Nutrition, and Allergies (NDA) EFSA J. 2015;13:1–84. [Google Scholar]
Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917. [PubMed] [Google Scholar]
Guo L, Zhu H, Lin C, et al. Associations between antioxidant vitamins and the risk of invasive cervical cancer in Chinese women: A case-control study. Sci Rep. 2015;5:13607. [PMC free article] [PubMed] [Google Scholar]
Hacker NF. In: Principles of cancer therapy, essentials of obstetrics and gynaecology . 2nd edition. Hacker N.F, Moore J.G, editors. Saunders W.B. Company; 2001. pp. 613–24. [Google Scholar]
Kamijo Y, Ichikawa M. Cost information of chemotherapy for cervical and endometrial cancer in Japan. Japan J Nurs Sci. 2014;11:190–9. [PubMed] [Google Scholar]
Lachance JA, Darus CJ, Stukenborg GJ, et al. A cost comparison of two strategies for treating stage IB2 cervical cancer. Int J Gynecol Cancer. 2008;18:274–8. [PubMed] [Google Scholar]
Matos A, Moutinho J, Pinto D, Medeiros R. The influence of smoking and other cofactors on the time to onset to cervical cancer in a southern European population. Eur J Cancer Prev. 2005;14:485–91. [PubMed] [Google Scholar]
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: cervical cancer. National Comprehensive Cancer Network, Inc; 2006. [Google Scholar]
Osanai M, Lee GH. Increased expression of the retinoic acid-metabolizing enzyme CYP26A1 during the progression of cervical squamous neoplasia and head and neck cancer. BMC Res Notes. 2014;7:697. [PMC free article] [PubMed] [Google Scholar]
Ruiz RB, Hernandez M. Cancer chemoprevention by dietary phytochemicals. Epidemiol Evidence. 2016;94:13–9. [Google Scholar]
Sanif R. The Comparative effect of neoadjuvant chemotherapy or neoadjuvant chemotherapy with Vitamin A in locally advanced cervix carcinoma at general Hospital Muhammad Hoesin Palembang. PhD Thesis. MSU University, Malaysia; 2018. [Google Scholar]
Schwab CL, English DP, Roque DM, Santin AD. Taxanes: Their impact on gynaecologic malignancy. Anticancer Drugs. 25:522–35. [PMC free article] [PubMed] [Google Scholar]
Smith B, Cohn DE, Clements A, Tierney BJ, Straughn JM Jr. Is the progression free survival advantage of concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin in patients with advanced cervical cancer worth the additional cost? A cost-effectiveness analysis. Gynecol Oncol. 2013;130:416–20. [PubMed] [Google Scholar]
Uray IP, Dmitrovsky E, Brown PH, et al. Retinoids and rexinoid in cancer prevention: from laboratory to clinic. Semin Oncol. 2016;43:49–64. [PMC free article] [PubMed] [Google Scholar]
Wang Y, Wang G, Wei LH, et al. Neoadjuvant chemotherapy for locally advanced cervical cancer reduces surgical risk and lymph-vascular space involvement. Chin J Cancer. 2011;30:645–54. [PMC free article] [PubMed] [Google Scholar]
Whitworth JM, Londoño-Joshi AI, Sellers JC, et al. The impact of novel retinoids in combination with platinum chemotherapy on ovarian cancer stem cells. Gynecol Oncol. 2012;125:226–30. [PMC free article] [PubMed] [Google Scholar]
Word Health Organization. International Agency for Research on Cancer. 2013. Press Release N 223. 12 December 2013. [Google Scholar]
Wiebe E, Denny L, Thomas G. Cancer of the cervix uteri. Int J Gynaecol Obstet. 2012;119:100–9. [PubMed] [Google Scholar]
Yang Z, Chen D, Zhang J, et al. The efficacy and safety of neoadjuvant chemotherapy in the treatment of locally advanced cervical cancer: A randomized multicentre study. Gynecol Oncol. 2016;141:230–1. [PubMed] [Google Scholar]
Yun YH, Kim YA, Min YH, et al. The influence of hospital volume and surgical treatment delay on long-term survival after cancer surgery. Ann Oncol. 2012;23:2731–7. [PubMed] [Google Scholar]
Zhang Y, Rishi AK, Dawson MI, et al. S-phase Arrest and apoptosis induced in normal mammary epithelial cells by a novel retinoid. Cancer Res. 2000;60:2025–32. [PubMed] [Google Scholar]